Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Clinicopathological determinants of positron emission tomography computed tomography fluorodeoxyglucose standardised uptake value in head and neck carcinoma.

Ozer E, Naiboglu B, Karapinar U, Agrawal A, Ozer HG, Schuller DE.

J Laryngol Otol. 2013 Jul;127(7):676-80. doi: 10.1017/S002221511300128X. Epub 2013 Jun 21.

PMID:
23790108
2.

Utility of quantitative 18 F-fluorodeoxyglucose uptake measurement to identify occult tonsillar carcinoma in patients with cervical metastasis of unknown primary tumours: a retrospective case-control study.

Lee HJ, Kim JS, Roh JL, Lee JH, Cho KJ, Park GC, Choi SH, Nam SY, Kim SY.

Clin Otolaryngol. 2013 Feb;38(1):30-8. doi: 10.1111/coa.12055.

PMID:
23167514
3.

The added value of 18F-fluorodeoxyglucose positron emission tomography computed tomography in patients with neck lymph node metastases from an unknown primary malignancy.

Prowse SJ, Shaw R, Ganeshan D, Prowse PM, Hanlon R, Lewis-Jones H, Wieshmann H.

J Laryngol Otol. 2013 Aug;127(8):780-7. doi: 10.1017/S002221511300162X. Epub 2013 Aug 7.

PMID:
23919968
4.

Dual-time-point fluorodeoxyglucose positron emission tomography for diagnosis of cervical lymph node metastases in patients with head and neck squamous cell carcinoma.

Nakamura S, Okochi K, Kurabayashi T.

J Comput Assist Tomogr. 2011 Mar-Apr;35(2):303-7. doi: 10.1097/RCT.0b013e31820a0af2.

PMID:
21412108
5.

Comparing staging by positron emission tomography with contrast-enhanced computed tomography and by pathology in head and neck squamous cell carcinoma.

Qualliotine JR, Mydlarz WK, Chan JY, Zhou X, Wang H, Agrawal N.

J Laryngol Otol. 2015 Dec;129(12):1213-9. doi: 10.1017/S0022215115002698. Epub 2015 Oct 22.

PMID:
26490394
6.

The role of positron emission tomography with 18F-fluorodeoxyglucose in nodal staging of clinical and radiological N₀ head and neck cancers.

Cetin B, Atasever T, Akdemir UO, Senturk S, Tufan G, Turan N, Buyukberber S, Coskun U, Benekli M.

Eur Arch Otorhinolaryngol. 2013 Aug;270(8):2307-13. doi: 10.1007/s00405-012-2337-4. Epub 2013 Jan 3.

PMID:
23283243
7.

Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.

Adams S, Baum RP, Stuckensen T, Bitter K, Hör G.

Eur J Nucl Med. 1998 Sep;25(9):1255-60.

PMID:
9724374
8.

[Correlation between PET-CT 18FDG uptake in primary lesions and clinicopathological parameters in esophageal carcinoma patients].

Feng R, Li MH, Kong L, Shi F, Yang GR, Yu JM.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):452-4. Chinese.

PMID:
19950557
9.

Diagnostic value of only 18F-fluorodeocyglucose positron emission tomography/computed tomography-positive lymph nodes in head and neck squamous cell carcinoma.

Lee SH, Huh SH, Jin SM, Rho YS, Yoon DY, Park CH.

Otolaryngol Head Neck Surg. 2012 Oct;147(4):692-8. Epub 2012 Apr 24.

PMID:
22535915
10.

Defining PET standardized uptake value threshold for tumor delineation with metastatic lymph nodes in head and neck cancer.

Suzuki O, Nishiyama K, Morimoto M, Hashiguchi H, Tanaka K, Nakajima A, Nakamura S, Yoshino K.

Jpn J Clin Oncol. 2012 Jun;42(6):491-7. doi: 10.1093/jjco/hys049. Epub 2012 Apr 29.

PMID:
22547728
11.

[Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].

Di Martino E, Nowak B, Krombach GA, Sellhaus B, Hausmann R, Cremerius U, Büll U, Westhofen M.

Laryngorhinootologie. 2000 Apr;79(4):201-6. German.

PMID:
10838683
12.

Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.

Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K, Murakami D, Tomiguchi S, Oya N, Katsuragawa S, Yamashita Y.

Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):377-82. Epub 2007 Feb 22.

PMID:
17321066
13.

Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck.

Fischbein NJ, AAssar OS, Caputo GR, Kaplan MJ, Singer MI, Price DC, Dillon WP, Hawkins RA.

AJNR Am J Neuroradiol. 1998 Aug;19(7):1189-96.

14.
15.

18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers--an audit and review of published studies.

Wong WL, Sonoda LI, Gharpurhy A, Gollub F, Wellsted D, Goodchild K, Lemon C, Farrell R, Saunders M.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):190-5. doi: 10.1016/j.clon.2011.11.001. Epub 2011 Dec 17. Review.

PMID:
22183080
16.

Effect of time-of-flight technique on the diagnostic performance of 18F-FDG PET/CT for assessment of lymph node metastases in head and neck squamous cell carcinoma.

Li CY, Klohr S, Sadick H, Weiss C, Hoermann K, Schoenberg SO, Sadick M.

J Nucl Med Technol. 2014 Sep;42(3):181-7. doi: 10.2967/jnmt.114.141192. Epub 2014 Jun 26.

17.

The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical lymph node metastases of unknown primary tumour.

de Bree R.

Eur Arch Otorhinolaryngol. 2010 Nov;267(11):1653-5. doi: 10.1007/s00405-010-1372-2. No abstract available.

18.

Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck.

Schmid DT, Stoeckli SJ, Bandhauer F, Huguenin P, Schmid S, von Schulthess GK, Goerres GW.

Laryngoscope. 2003 May;113(5):888-91.

PMID:
12792328
19.

Positron emission tomography in cancer of the head and neck.

Hain SF.

Br J Oral Maxillofac Surg. 2005 Feb;43(1):1-6.

PMID:
15620766
20.

The use of multiple time point dynamic positron emission tomography/computed tomography in patients with oral/head and neck cancer does not predictably identify metastatic cervical lymph nodes.

Carlson ER, Schaefferkoetter J, Townsend D, McCoy JM, Campbell PD Jr, Long M.

J Oral Maxillofac Surg. 2013 Jan;71(1):162-77. doi: 10.1016/j.joms.2012.03.028. Epub 2012 Jun 26.

PMID:
22742956

Supplemental Content

Support Center